A Phase 2A Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Trial of PQ912 in Subjects with early Alzheimer's Disease

Trial Profile

A Phase 2A Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Trial of PQ912 in Subjects with early Alzheimer's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs PQ 912 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms SAPHIR
  • Sponsors Probiodrug
  • Most Recent Events

    • 30 Nov 2017 According to a Probiodrug media release, data from the study has been presented in November 2017 at Clinical Trials on Alzheimer's Disease (CTAD) 2017 Conference.
    • 26 Oct 2017 According to a Probiodrug media release, data will be presented at Clinical Trials on Alzheimer's Disease (CTAD) 2017 Conference.
    • 11 Jun 2017 According to a Probiodrug media release, additional analysis of all endpoints, CSF biomarker and subpopulations will continue during the next several months and the full results of this trial study are intended to be reported at scientific congresses and published in scientific journals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top